BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Katsanos KH, Koutroumpakis E, Giagkou E, Malakos Z, Almpani E, Skamnelos A, Christodoulou DK. Fast-track drug approval in inflammatory bowel diseases. Ann Gastroenterol 2016;29:439-44. [PMID: 27708508 DOI: 10.20524/aog.2016.0051] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
Number Citing Articles
1 Yoon JY, Shin JE, Park SH, Park DI, Cha JM. Disability due to Inflammatory Bowel Disease Is Correlated with Drug Compliance, Disease Activity, and Quality of Life. Gut Liver 2017;11:370-6. [PMID: 28208008 DOI: 10.5009/gnl16422] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
2 Xu C, Ghali S, Wang J, Shih DQ, Ortiz C, Mussatto CC, Lee EC, Tran DH, Jacobs JP, Lagishetty V, Fleshner P, Robbins L, Vu M, Hing TC, McGovern DPB, Koon HW. CSA13 inhibits colitis-associated intestinal fibrosis via a formyl peptide receptor like-1 mediated HMG-CoA reductase pathway. Sci Rep 2017;7:16351. [PMID: 29180648 DOI: 10.1038/s41598-017-16753-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]